Literature DB >> 20840002

Infection disclosure in the injecting dyads of Hungarian and Lithuanian injecting drug users who self-reported being infected with hepatitis C virus or human immunodeficiency virus.

V Anna Gyarmathy1, Alan Neaigus, Nan Li, Eszter Ujhelyi, Irma Caplinskiene, Saulius Caplinskas, Carl A Latkin.   

Abstract

The aim of this study was to assess the prevalence and correlates of disclosure to network members of being hepatitis C virus (HCV)- or human immunodeficiency virus (HIV)-infected among injecting dyads of infected injection drug users (IDUs) in Budapest, Hungary and Vilnius, Lithuania,. Multivariate generalized estimating equations (GEE) were used to assess associations. Very strong infection disclosure norms exist in Hungary, and HCV disclosure was associated with using drugs and having sex within the dyad. Non-ethnic Russian IDUs in Lithuania were more likely to disclose HCV infection to non-Roma, emotionally close and HCV-infected network members, and to those with whom they shared cookers, filters, drug solutions or rinse water or got used syringes from, and if they had fewer non-IDU or IDU network members. Ethnic Russian Lithuanian IDUs were more likely to disclose HCV if they had higher disclosure attitude and knowledge scores, 'trusted' network members, and had lower non-injecting network density and higher injecting network density. HIV-infected Lithuanian IDUs were more likely to disclose to 'trusted' network members. Disclosure norms matched disclosure behaviour in Hungary, while disclosure in Lithuania to 'trusted' network members suggests possible stigmatization. Ongoing free and confidential HCV/HIV testing services for IDUs are needed to emphasize and strengthen disclosure norms, and to decrease stigma.

Entities:  

Mesh:

Year:  2010        PMID: 20840002      PMCID: PMC3074185          DOI: 10.3109/00365548.2010.513064

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  21 in total

1.  Selective risk taking among needle exchange participants: implications for supplemental interventions.

Authors:  T W Valente; D Vlahov
Journal:  Am J Public Health       Date:  2001-03       Impact factor: 9.308

2.  Severity of dependence and route of administration of heroin, cocaine and amphetamines.

Authors:  M Gossop; P Griffiths; B Powis; J Strang
Journal:  Br J Addict       Date:  1992-11

3.  HIV serostatus disclosure to sexual partners among HIV-positive injection drug users.

Authors:  Jeffrey T Parsons; Whitney Missildine; Jason Van Ora; David W Purcell; Cynthia A Gómez
Journal:  AIDS Patient Care STDS       Date:  2004-08       Impact factor: 5.078

4.  Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty.

Authors:  Tim Rhodes; Mark Davis; Ali Judd
Journal:  Addiction       Date:  2004-05       Impact factor: 6.526

5.  HCV status knowledge and risk behaviours amongst intravenous drug users.

Authors:  G Vidal-Trécan; J Coste; I Varescon-Pousson; B Christoforov; A Boissonnas
Journal:  Eur J Epidemiol       Date:  2000-05       Impact factor: 8.082

6.  Knowledge of HIV serostatus and preventive behaviour among European injecting drug users. The European Community Study Group on HIV in Injecting Drug Users.

Authors:  J C Desenclos; G Papaevangelou; R Ancelle-Park
Journal:  AIDS       Date:  1993-10       Impact factor: 4.177

Review 7.  The network approach and interventions to prevent HIV among injection drug users.

Authors:  A Neaigus
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

8.  Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland.

Authors:  Danielle C Ompad; Crystal M Fuller; David Vlahov; David Thomas; Steffanie A Strathdee
Journal:  Clin Infect Dis       Date:  2002-09-03       Impact factor: 9.079

9.  "Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001.

Authors:  Don C Des Jarlais; Theresa Perlis; Kamyar Arasteh; Holly Hagan; Judith Milliken; Naomi Braine; Stanley Yancovitz; Donna Mildvan; David C Perlman; Carey Maslow; Samuel R Friedman
Journal:  J Acquir Immune Defic Syndr       Date:  2004-02-01       Impact factor: 3.731

10.  The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users.

Authors:  Carol F Kwiatkowski; Karen Fortuin Corsi; Robert E Booth
Journal:  Addiction       Date:  2002-10       Impact factor: 6.526

View more
  8 in total

1.  Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs.

Authors:  Megan G Hofmeister; Jennifer R Havens; April M Young
Journal:  J Prim Prev       Date:  2017-10

Review 2.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

3.  A simulative comparison of respondent driven sampling with incentivized snowball sampling--the "strudel effect".

Authors:  V Anna Gyarmathy; Lisa G Johnston; Irma Caplinskiene; Saulius Caplinskas; Carl A Latkin
Journal:  Drug Alcohol Depend       Date:  2013-12-03       Impact factor: 4.492

4.  Cost-effectiveness of alternative strategies for provision of HIV preexposure prophylaxis for people who inject drugs.

Authors:  Rui Fu; Douglas K Owens; Margaret L Brandeau
Journal:  AIDS       Date:  2018-03-13       Impact factor: 4.177

5.  Anti-HCV prevalence in the general population of Lithuania.

Authors:  Valentina Liakina; Jonas Valantinas
Journal:  Med Sci Monit       Date:  2012-03

6.  Injecting-related trust, cooperation, intimacy, and power as key factors influencing risk perception among drug injecting partnerships.

Authors:  Meghan D Morris; Erin Andrew; Judy Y Tan; Lisa Maher; Colleen Hoff; Lynae Darbes; Kimberly Page
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

7.  How close are we to hepatitis C virus elimination in Central Europe?

Authors:  Robert Flisiak; Sona Frankova; Ivica Grgurevic; Bela Hunyady; Peter Jarcuska; Limas Kupčinskas; Michael Makara; Marieta Simonova; Jan Sperl; Ieva Tolmane; Adriana Vince; Dorota Zarębska-Michaluk
Journal:  Clin Exp Hepatol       Date:  2020-02-17

Review 8.  Analysis of duration of risk behaviour for key populations: a literature review.

Authors:  Erika Fazito; Paloma Cuchi; Mary Mahy; Tim Brown
Journal:  Sex Transm Infect       Date:  2012-12       Impact factor: 3.519

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.